Melanomas are inherently aggressive cancers for which basic and translational research have significantly improved patient prognosis. Nevertheless, clinical responses are still incomplete. The long-term goals of our Group are to identify new progression biomarkers and to validate more effective therapeutic agents. We are particularly interested in mechanisms of cellular stress that, being selectively deregulated in melanoma, define lineage-specific vulnerabilities (publications in Nature, Cancer Cell, Nature Cell Biology, Nature Communications, among others). Our laboratory has also reported the first-in-class lymphoreporter (MetAlert) mice for non-invasive imaging of pre-metastatic niches in melanoma (Nature). These systems led to the identification of new mechanisms of immune resistance (Nature Medicine) and the generation of nanoparticle-based treatments (Cancer Cell, EMBO Mol Med), with derivatives now being tested in clinical trials. Our ultimate objective is to improve the management of patients with otherwise refractory metastatic melanomas.
- Nuria Gago
- David Olmeda
- Adriana Sanna
- Xavier Catena
- Marta Contreras
- Guillermo De la Vega
- Naiara Juan
- Sergio Oterino
- Thelma Poluha
- José Antonio Torres
- Tonantzin Guadalupe Calvo
- Cynthia Mucientes
- Mireia Vallespinós
- (2023). T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis.. Immunity 56, 143-161. CNIO Publication.
- (2022). Cell position matters in tumour development. Nature 604, 248-250. CNIO Publication.
- (2022). Lipid droplet degradation by autophagy connects mitochondria metabolism to Prox1-driven expression of lymphatic genes and lymphangiogenesis. Nat Commun 13, 2760. CNIO Publication.
- (2021). Melanoma models for the next generation of therapies. Cancer Cell 39, 610-631. CNIO Publication.
- (2021). Physiological models for in vivo imaging and targeting the lymphatic system: Nanoparticles and extracellular vesicles. Adv Drug Deliver Rev 175, 113833. CNIO Publication.
- (2021). The State of Melanoma: Emergent Challenges and Opportunities. Clin Cancer Res 27, 2678-2697. CNIO Publication.
- (2021). Live imaging of neolymphangiogenesis identifies acute antimetastatic roles of dsRNA mimics. EMBO Mol Med 13, e12924. CNIO Publication. Open Access
- (2020). Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state. Nat Med 26, 1865-1877. CNIO Publication.
- (2020). Lymph: (Fe)rrying Melanoma to Safety. Cancer Cell 38, 446-448. CNIO Publication.
- (2019). p62/SQSTM1 Fuels Melanoma Progression by Opposing mRNA Decay of a Selective Set of Pro-metastatic Factors.. Cancer Cell 35, 46-63. CNIO Publication.
- (2019). p62/SQSTM1 Fuels Melanoma Progression by Opposing mRNA Decay of a Selective Set of Pro-metastatic Factors. Cancer Cell 35, 46-63. CNIO Publication.
- (2019). KLF9-dependent ROS regulate melanoma progression in stage-specific manner. Oncogene 38, 3585-3597. CNIO Publication.
- (2019). Antimetastatic dsRNA mimics identified by live imaging of pathogenic neolymphangiogenes. BioRivx (in press). CNIO Publication.
- (2018). CD38 promotes pristane-induced chronic inflammation and increases susceptibility to experimental lupus by an apoptosis-driven and TRPM2-dependent mechanism. Sci Rep 8, 3357. CNIO Publication. Open Access